Chronic hepatitis B and C

References

• Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991: 11: 84–92
   PubMed Web of Science ®Google Scholar
• Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990: 264: 2231–5
   PubMed Web of Science ®Google Scholar
• Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989: 9(4): 235–9
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Di Bisceglie AM. Treatment of chronic type C hepatitis with alpha interferon. Semin Liver Dis 1989: 9(4): 259–63
   PubMed Web of Science ®Google Scholar
• Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease: effects of interferon alfe therapy. N Engl J Med 1991: 324(14): 933–40
   PubMed Web of Science ®Google Scholar
• Greenberg HB, Pollard RB, Lutwick LI, et al. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976: 295(10): 517–22
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988: 95(5): 1318–25
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Schiff ER, Davis GL, et al. Arandomized, controlled trial of interferon alfe- 2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990: 323(5): 295–301
   PubMed Web of Science ®Google Scholar
• Lok AS, Ma OC, Lau JY. Interferon alfetherapy in patients with chronic hepatitis B virus infection: effects on hepatitis B virus DNA in the liver. Gastroenterology 1991: 100(3): 756–61
   PubMed Web of Science ®Google Scholar
• Caselmann WH, Eisenburg J, Hofschneider PH, et al. Beta- and gamma-interfer- on in chronic active hepatitis B: a pilot trial of short-term combination therapy. Gastroenterology 1989: 96(2 Pt 1): 449–55
   PubMed Web of Science ®Google Scholar
• Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989: 10(5): 761–3
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Wu PC, et al. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988: 2(8606): 298–302
   PubMed Web of Science ®Google Scholar
• Lok AS, Ma OC, Lai CL, et al. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis 1989: 9: 249–53
   PubMed Web of Science ®Google Scholar
• Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991: 114(8): 629–34
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Brant EM. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and heparins B surface antigen. Ann Intern Med 1991; 115(2): 113–5
   PubMed Web of Science ®Google Scholar
• Garcia G, Smith CI, Weissberg JI, et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B: a randomized, double-blinded, placebo-controlled trial. Ann Intern Med 1987: 107(3): 278–85
   PubMed Web of Science ®Google Scholar
• Alexander GJ, Fagan EA, Hegarty JE, et al. Controlled trial of acyclovir in chronic hepatitis B virus infection. J Med Virol 1987: 21: 81–7
   PubMed Web of Science ®Google Scholar
• Hess G, Rossol S, Voth R, et al. Treatment of patients with chronic type B hepatitis and concurrent human immunodeficiency virus infection with a combination of interferon alpha and azidothymidine: a pilot study. Digestion 1989: 43(1–2): 56–9
   PubMed Web of Science ®Google Scholar
• Thyagarajan SP, Subramanian S, Thirunalasundari T, et al. Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 1988: 2(8614): 764–6
   PubMed Web of Science ®Google Scholar
• Hedin G, Weiland O, Ljunggren K, et al. Treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection with foscarnet. Prog Clin Biol Res 1987: 234: 309–20
   PubMedGoogle Scholar
• Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991: 14(3): 409–15
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986: 315(25): 1575–8
   PubMed Web of Science ®Google Scholar
• Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfe: a multicenter randomized, controlled trial. N Engl J Med 1989: 321(22): 1501–6
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfe therapy for chronic hepatitis C: a randomized, doubleblind, placebo-controlled trial. N Engl J Med 1989: 321 (22): 1506–10
   PubMed Web of Science ®Google Scholar
• Realdi G, Diodati G, Bonetti P, et al. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis: preliminary results of a randomized, controlled trial. J Hepatol 1990;11(Suppl 1): S68–71
   PubMed Web of Science ®Google Scholar
• Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991: 13(3): 393–7
   PubMed Web of Science ®Google Scholar
• Shindo M, Di Bisceglie AM, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991: 115(9): 700–4
   PubMed Web of Science ®Google Scholar
• Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfe-2b and placebo in patients with chronic non-A non-B hepatitis. Gastroenterology 1991: 101(2): 497–502
   PubMed Web of Science ®Google Scholar
• Saez-Royuela F, Porres JC, Moreno A, et al. High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 1991: 13(2): 327–31
   PubMed Web of Science ®Google Scholar
• Omata M, Yokosuka O, Takano S, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991: 338(8772): 914–5
   PubMed Web of Science ®Google Scholar
• Reichard O, Andersson J, Schvarcz R, et al. Ribavirin treatment for chronic hepatitis C. Lancet 1991: 337(8749): 1058–61
   PubMed Web of Science ®Google Scholar
• Crosignani A, Battezzati PM, Setchell KD, et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study. Hepatology 1991: 13(2): 339–44
   PubMed Web of Science ®Google Scholar